A recent study further showed that the synthetic lethal interaction between CREBBP and EP300 was obtained in both normal germinal centre B cells and CREBBP-mutant DLBCL cells, raising the possibility of targeting EP300 in the treatment of CREBBP-mutated tumours22. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.